BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 23229016)

  • 21. Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients.
    Zhong JS; Meng FY; Xu D; Zhou HS; Dai M
    Acta Haematol; 2012; 127(4):221-7. PubMed ID: 22473087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.
    Singh O; Chan JY; Lin K; Heng CC; Chowbay B
    PLoS One; 2012; 7(12):e51771. PubMed ID: 23272163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.
    Takahashi N; Miura M; Scott SA; Kagaya H; Kameoka Y; Tagawa H; Saitoh H; Fujishima N; Yoshioka T; Hirokawa M; Sawada K
    J Hum Genet; 2010 Nov; 55(11):731-7. PubMed ID: 20720558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.
    Inokuchi K; Yamaguchi H; Tamai H; Dan K
    J Clin Exp Hematop; 2012; 52(2):145-7. PubMed ID: 23037633
    [No Abstract]   [Full Text] [Related]  

  • 26. ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.
    Ali MA; Elsalakawy WA
    Med Oncol; 2014 Nov; 31(11):279. PubMed ID: 25301112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
    Ben Hassine I; Gharbi H; Soltani I; Ben Hadj Othman H; Farrah A; Amouri H; Teber M; Ghedira H; Ben Youssef Y; Safra I; Abbes S; Menif S
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):829-839. PubMed ID: 28836054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of hOCT1 and ABCB1 gene on the efficacy of imatinib mesylate in chronic myelocytic leukemia].
    Chen WW; Meng FY; Zhong JS; Yin CX; Wang ZX
    Zhonghua Yi Xue Za Zhi; 2012 May; 92(20):1405-8. PubMed ID: 22883199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
    Mencalha AL; Corrêa S; Salles D; Du Rocher B; Santiago MF; Abdelhay E
    BMC Cancer; 2014 Nov; 14():866. PubMed ID: 25417721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations.
    San José-Enériz E; Román-Gómez J; Jiménez-Velasco A; Garate L; Martin V; Cordeu L; Vilas-Zornoza A; Rodríguez-Otero P; Calasanz MJ; Prósper F; Agirre X
    Mol Cancer; 2009 Sep; 8():69. PubMed ID: 19723306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model.
    Pinto CA; DE Sousa Portilho AJ; Barbosa MC; DE Moraes MEA; DE Lemos JAR; Burbano RMR; Moreira-Nunes CA
    In Vivo; 2021; 35(5):2661-2667. PubMed ID: 34410954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.
    Kosztyu P; Bukvova R; Dolezel P; Mlejnek P
    Chem Biol Interact; 2014 Aug; 219():203-10. PubMed ID: 24954033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apoptosis-related gene expression profile in chronic myeloid leukemia patients after imatinib mesylate and dasatinib therapy.
    Ferreira AF; de Oliveira GLV; Tognon R; Collassanti MDS; Zanichelli MA; Hamerschlak N; de Souza AM; Covas DT; Kashima S; de Castro FA
    Acta Haematol; 2015; 133(4):354-364. PubMed ID: 25721555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p-Stat3 and bcr/abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy.
    Sayed D; Badrawy H; Gaber N; Khalaf MR
    Leuk Res; 2014 Feb; 38(2):243-50. PubMed ID: 24374144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Role of Lyn kinase in imatinib-resistant chronic myelogenous leukemia].
    Liu J; Zhao XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1352-5. PubMed ID: 23257431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.
    Ye YX; Zhou J; Zhou YH; Zhou Y; Song XB; Wang J; Lin L; Ying BW; Lu XJ
    Asian Pac J Cancer Prev; 2014; 15(22):9961-6. PubMed ID: 25520136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter.
    Corrêa S; Binato R; Du Rocher B; Ferreira G; Cappelletti P; Soares-Lima S; Pinto LF; Mencalha A; Abdelhay E
    Epigenetics; 2014 Aug; 9(8):1172-83. PubMed ID: 25089713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.
    Balabanov S; Gontarewicz A; Keller G; Raddrizzani L; Braig M; Bosotti R; Moll J; Jost E; Barett C; Rohe I; Bokemeyer C; Holyoake TL; Brümmendorf TH
    PLoS One; 2011 Apr; 6(4):e19164. PubMed ID: 21541334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
    Marin D; Bazeos A; Mahon FX; Eliasson L; Milojkovic D; Bua M; Apperley JF; Szydlo R; Desai R; Kozlowski K; Paliompeis C; Latham V; Foroni L; Molimard M; Reid A; Rezvani K; de Lavallade H; Guallar C; Goldman J; Khorashad JS
    J Clin Oncol; 2010 May; 28(14):2381-8. PubMed ID: 20385986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.